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Introduction
Tariquidar (TQD, Xenova, UK) is a third-generation
inhibitor of the multidrug efflux transporter P-glycopro-
tein (P-gp) with potential applications in neurology and
oncology in order to increase drug exposure of tissues tar-
geted for treatment. We used small-animal positron emis-
sion tomography (μPET) with the P-gp substrate (R)-
[11C]verapamil (VPM) in order to measure in vivo the
degree of P-gp inhibition at the rat blood-brain barrier
(BBB) after administration of different doses of TQD.
Methods
Wistar Unilever rats received intravenous doses of 0, 1, 3,
5, 7.5 and 15 mg/kg of TQD followed by a 1-hour VPM
μPET scan recorded at 2 hours after TQD administration.
Brain-to-plasma radioactivity ratios were fitted to a sig-
moidal dose-response curve.
Results
TQD inhibited P-gp-mediated efflux of VPM across the
BBB with an apparent half-maximum effective dose
(ED50) of 6.6 mg/kg (95% confidence interval: 4.9–8.2
mg/kg) which was in good agreement with previous data
reported in mice for another P-gp substrate (loperamide,
ED50: 5.7 mg/kg) [1]. Brain-to-plasma radioactivity ratios
after 0 and 15 mg/kg of TQD were 0.23 and 3.15, respec-
tively.
Conclusion
Our data suggest that TQD is a potent inhibitor of P-gp at
the rat BBB. Moreover, VPM PET appears to be a useful
tool for in vivo dose finding of novel P-gp inhibitors in
animals and humans.
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